Mitochondria are important regulators of cellular energy and metabolism and play a crucial role in numerous diseases including cancer and cardiac disease. They generate a membrane potential gradient providing energy required for ATP synthesis [1]. 4-[18F]-Fluorobenzyltriphenylphosphonium cation ([18F]-FBnTP) is a positively charged lipophilic compound used as a negative membrane potential targeting PET-tracer for myocardial perfusion imaging (MPI) [2]. The precursor (ABX prod. no. 7058) to produce [18F]FBnTP via copper-mediated one step 18F-fluorination reaction and its reference compound (ABX prod. no. 7059) are available for research and development.
[1] Mitchell, P. Evidence discriminating between the chemical and the chemiosmotic mechanisms of electron transport phosphorylation. Nature 1965, 208 (5016), 1205–1206. [2] Zhang, Z. One‐step synthesis of 4‐[18F]fluorobenzyltriphenylphosphonium cation for imaging with positron emission tomography. J. Label Compd. Radiopharm 2016, 1–5.
ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.
Based in Radeberg, Germany, and founded in 1997, our team of about 400 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards.
ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.
